VIDEO: Directional deep brain stimulation: novel treatment options for all Parkinson’s patients
sponsored by Boston Scientific
Author: SPONSOREDPublished: 4 October 2017
Prep: Cook: Serves:
Watch deep brain stimulation (DBS) experts Professor Pollo, Professor Timmermann, Professor Visser-Vanderwalle and Professor Volkmann explain the benefits of novel directional DBS systems for improved symptom control and fewer side effects
Every human brain is unique and every course of Parkinson’s disease has its own characteristics. In deep brain stimulation (DBS) therapy, physicians aim to target a very specific part of the brain – the subthalamic nucleus – in order to mitigate Parkinson’s symptoms.
Up until now, conventional DBS systems only allowed for stimulation with ring electrodes. With these electrodes, stimulation took the form of a ring around the electrode in the lead that was implanted into the patient’s brain. This meant that while physicians tried to target a very specific area of the brain, they always ran the risk of stimulating its neighbouring regions – since they could not steer the stimulation precisely. Unintended and unwanted stimulation could cause side effects such as speech problems.
The latest generation of DBS devices allow physicians to precisely steer the stimulation to target one specific area of the brain – significantly reducing side effects from unwanted stimulation. Our directional DBS systems use novel lead designs with segmented electrodes that allow the activation of individual electrode contacts. In addition, the technology in the pulse generator that powers the leads – the Multiple Independent Current Control (MICC) technology – allows the physician to specify exactly the amount of current needed for every contact of the electrode.
Through activating specific electrode contacts, and defining the amount of stimulation for each contact, stimulation precision is significantly increased. It is similar to shining a light on a specific spot with a flashlight. With the new systems, physicians now have full control of the stimulation steering and an increased set of stimulation options.
About deep brain stimulation (DBS) therapy
DBS uses a stimulator that is implanted into the patient’s chest. The stimulator sends mild electrical impulses to specific areas of the brain via thin wires called leads. This stimulation may help improve day-to-day experiences for people living with movement disorders such as Parkinson’s disease, dystonia, or essential tremor.
For comprehensive information on deep brain stimulation and Parkinson’s, please visit the EPDA website.
This article is sponsored by Boston Scientific. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Meet Julie Dodd, director of digital transformation at Parkinson’s UK
“I know many fantastic female leaders in the charity sector”
7 days ago
World War II weapon antidote could treat Parkinson’s
Researchers at Purdue University, US, are studying a World War II chemical weapon antidote that they believe could be used to treat Parkinson’s. It is believed the antidote, called dimercaprol, may be able to remove acrolein – a toxin that poisons neurons and can lead to the development of Parkinson’s disease. In addition to this, researchers believe dimercaprol can increase the survival rate of brain cells, improve mobility and reduce symptoms of pain. Riyi Shi, professor of neuroscience and biomedical engineering at Purdue University, said: “Our studies show that by removing the toxin (acrolein) from the brain, we are not just reducing the symptoms of Parkinson’s disease but also significantly reversing the damage of Parkinson’s disease. This could actually provide a new treatment for Parkinson’s patients.”
Repurposed cancer drug shows promise for Parkinson’s
Researchers at the Oxford Parkinson’s Disease Centre, UK, have repurposed an experimental cancer drug – called tasquinimod – as a potential treatment for Parkinson’s. The study – funded by Parkinson’s UK and published in science journal ‘Cell Stem Cell’ – has been tested on a total of 10 patients so far. As part of the research, the study grew brain cells from donated skin cell samples of people living with a rare genetic form of Parkinson’s – this process was then repeated on people with a common non-genetic form of the condition. Researchers found that tasquinimod can block HDAC4, a protein that causes Parkinson’s genes to become inactive. Professor Richard Wade-Martins, co-lead author of the study, said: “We think that switching off these genes in brain cells may play a vital role in the cell damage and death that occurs in Parkinson’s.”
Research survey assesses impact of holidays on Parkinson’s symptoms
The Radboud University Medical Center, Netherlands, is seeking participants for an online survey assessing the effects of a holiday on Parkinson’s. The study will assess whether a vacation can have physical and mental benefits for people living with the condition. It will also look at which specific factors, such as temperature and physical activity, can alleviate or increase symptoms. The Michael J Fox Foundation has approved the study’s protocol. Participants can sign up to complete the 20-minute survey online. The survey is open to anyone over 18 who has Parkinson’s and has been on vacation once or more between 1 June 2016 and 30 September 2018. Marjan Faber, the study’s daily supervisor, said: “If the study is able to identify decisive factors, those can act as a starting point for novel approaches in care for people with Parkinson’s disease.” To apply please visit research platform ParkinsonNEXT.